• Sabutoclax: A Better Way to Read Apoptosis Assays

  2026-08-23

  Sabutoclax is a pan-Bcl-2 inhibitor suited to mechanistic cancer research, but its value depends on separating cytostasis from true cell killing. This article presents an assay interpretation framework that connects target engagement, apoptosis induction in cancer cells, and translational model selection.

• DeferoxamineB in Ferroptosis Research: Practical Workflows

  2026-08-22

  DeferoxamineB is an iron-chelation tool for separating iron-dependent lipid damage from copper-driven and metabolism-linked tumor cell death. This guide translates its chemistry into reproducible cell-culture workflows, controls, and troubleshooting strategies aligned with recent ferroptosis–cuproptosis research.

• ABT-263: Designing Better Apoptosis Assays

  2026-08-21

  ABT-263 and Navitoclax can do more than induce apoptosis: they can reveal whether a cancer model is primed, target-engaged, and competent to execute cell death. This guide connects Bcl-2 biology with rigorous assay design and a carefully bounded insight from synaptic signaling research.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows

  2026-08-20

  SCH772984 HCl enables direct interrogation of ERK1/2 signaling, adaptive pathway reactivation, and treatment resistance in BRAF- and RAS-driven models. This workflow-focused guide connects rapid phospho-ERK pharmacodynamics with longer-term proliferation, resistance, and TERT-related assays.

• TCEP Hydrochloride in DPC Proteolysis Assays

  2026-08-20

  Tris(2-carboxyethyl) phosphine hydrochloride is more than a routine disulfide-reduction reagent. This article explains how controlled redox chemistry can improve interpretation of ubiquitin-dependent DNA-protein crosslink proteolysis assays while preserving broader biochemical utility.

• RIPostC, Ketone Bodies, and Ferroptosis in Stroke

  2026-08-19

  This 2024 ACS Chemical Neuroscience study identifies ketone body metabolism as a mechanistic link between remote ischemic postconditioning and reduced ferroptotic injury after ischemic stroke. Its combination of rat middle cerebral artery occlusion, neuronal oxygen-glucose deprivation/reoxygenation, erastin challenge, and metabolic and iron-related readouts provides a framework for testing ketone body signaling in neuroprotection.

• Nicotinamide Riboside Chloride in RGC Translation

  2026-08-19

  A translational framework for using Nicotinamide Riboside Chloride (NIAGEN) to connect NAD+ biology with stem cell-derived retinal ganglion cell models, while keeping differentiation evidence, metabolic hypotheses, and product specifications analytically separate.

• Sabutoclax Workflows for Apoptosis Assays

  2026-08-18

  Sabutoclax is a permeable pan-Bcl-2 inhibitor for dissecting target-driven apoptosis, growth arrest, and cell-line selectivity. This workflow pairs concentration–response testing with time-resolved viability and death measurements to avoid mistaking cytostasis for apoptosis.

• Protoporphyrin IX for Ferroptosis Assays

  2026-08-18

  Use Protoporphyrin IX as a controlled photodynamic compound for light-dependent cancer assays, heme pathway studies, and mechanistic ferroptosis experiments. Its dual optical and iron-linked biology is powerful, but only when formulation, illumination, and dark controls are separated.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-08-17

  The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its preclinical data show bladder-enriched expression, restoration of tumor-suppressive p21 signaling, and significant tumor growth suppression, while also defining the delivery and validation steps relevant to nonviral mRNA therapy.

• 3-Hydroxybutyrate (BHBA) in Metabolic Research

  2026-08-17

  3-hydroxybutyrate (BHBA) is a fatty acid β-oxidation metabolite that functions as both a ketone body signaling molecule and a chromatin regulator. Evidence supports BHBA-centered models of ketosis and epigenetic regulation, while recent stroke research indicates that ketone-body effects on ferroptosis require metabolite-specific validation.

• LACTB Remodels Mitochondria to Drive Apoptosis

  2026-08-16

  Kamerkar and colleagues identify LACTB as a mitochondrial inner-membrane remodeling factor that promotes cytochrome c release during apoptosis. The study separates this function from BAX, Drp1, and OPA1 regulation, providing a mechanistic framework for understanding how tumor-suppressive LACTB activity can control mitochondrial cell death.

• Acifran: HCAR2/HCAR3 Lipid Signaling

  2026-08-15

  Acifran, also called (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a research agonist for HCAR2/GPR109A and HCAR3/GPR109B. Recent cryo-EM structures place Acifran in both receptor complexes and support its use as a mechanistic probe for lipid metabolism regulation, not as a diagnostic or therapeutic product.

• MCL-1’s Canonical Role in Breast Cancer Survival

  2026-08-14

  A study in Cell Death & Differentiation shows that breast cancer dependence on MCL-1 is primarily explained by its canonical anti-apoptotic activity. By combining acute genetic deletion, pharmacological inhibition, and BAX/BAK epistasis in clinically relevant models, the work links MCL-1 targeting to mitochondrial apoptosis and tumour control while clarifying important limits for translation.

• FITC Goat Anti-Mouse IgG: TIL Assay Strategy

  2026-08-14

  Explore how the FITC Goat Anti-Mouse IgG (H+L) Antibody supports quantitative spatial and cytometric readouts in TIL research. This guide connects secondary-antibody design with tumor-microenvironment studies, assay controls, and practical workflow decisions.

8009 records 1/534 page Next 12345 下5页 Last page